Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Genitourinary 3Gastrointestinal 3Breast 3Dermatologic 2Sarcoma 1Gynecologic 1

Conditions

Melanoma 7Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Kidney Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Glioma 1Endometrial Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma of Lung 1

Interventions

aldesleukin 15pembrolizumab 11Cyclophosphamide 9fludarabine phosphate 7fludarabine 6Nivolumab 6Interleukin-2 6atezolizumab 5Radiotherapy 5Ipilimumab 4Interferon-alpha 4Drug Therapy 4Blood Specimen Collection 4Radiosurgery 3tremelimumab 2temsirolimus 2durvalumab 2cemiplimab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Paclitaxel 2Metformin 2Interleukin-12 Subunit p35 2Genistein 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Cetuximab 2zanolimumab 1vivitrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × Cetuximab × Dermatologic × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03319459 2021-11-22

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
44 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡